Sumarago, Bb Boy .

HRN: 21-39-01  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/08/2022
AMPICILLIN 250MG (VIAL)
06/08/2022
06/14/2022
IV
90
Q12
Prematurity
Waiting Final Action 
06/08/2022
GENTAMICIN 40MG/ML, 2ML (AMP)
06/08/2022
06/14/2022
IV
9
Q26
Prematurity
Waiting Final Action 
06/10/2022
CEFTAZIDIME 1GM (VIAL)
06/10/2022
06/16/2022
IV
55mg
Q12hrs
Neonatal Sepsis
Waiting Final Action 
06/16/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
06/16/2022
06/22/2022
IVT
90mg
Q12
Neonatal Pneumonia
Waiting Final Action 
06/16/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
06/16/2022
06/22/2022
IVT
27mg
OD
Neonatal Pneumonia
Waiting Final Action 
06/22/2022
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
06/22/2022
06/29/2022
IV
27mg
Q8
RDS/ Neonatal Sepsis
Waiting Final Action 
06/22/2022
METRONIDAZOLE 125MG/5ML, 60ML (BOT)
06/22/2022
06/29/2022
IV
14 Mg
Q8
Neonatal Sepsis
Waiting Final Action 
06/23/2022
FLUCONAZOLE 150MG (CAP)
06/23/2022
06/30/2022
OGT
21
Od
Neonatal Sepsis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: